Search results
Hypertrophic Cardiomyopathy Guidelines Add Drug Class, Endorse More Exercise
MedPage Today· 3 days agoUpdates to national guidelines for the management of hypertrophic cardiomyopathy (HCM) endorse...
Exercise, new drug class recommended for management of hypertrophic cardiomyopathy
Medical Xpress· 3 days agoThe American College of Cardiology (ACC) and the American Heart Association (AHA) have released a...
Is exercise safe for people with an inherited heart condition?
San Francisco Chronicle· 3 days agoOver the years, people with a genetic condition causing thickening of the heart muscle, known as hypertrophic cardiomyopathy, have received confusing advice ...
Benefit for Local 5’s Shaun Kornusky & family taking place Friday at Stadium View
WFRV Green Bay via Yahoo News· 4 days agoGREEN BAY, Wis. (WFRV)—Shaun Kornusky, an account executive on the sales team at WFRV, has ...
Brazilian Society of Cardiology Updates Three Guidelines
Medscape· 1 day agoThe Brazilian Society of Cardiology (SBC) has just updated its guidelines on hypertension and...
Edgewise Therapeutics doses first subject in HCM drug trial
Clinical Trials Arena via Yahoo Finance· 4 days agoUS-based biopharmaceutical company Edgewise Therapeutics has dosed the first subject in the Phase II...
Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials
GuruFocus.com via Yahoo Finance· 23 hours agoAdditionally, Cytokinetics announced the initiation of CEDAR-HCM, a trial focusing on pediatric...
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $15.40
ETF DAILY NEWS· 14 hours agoTenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) has been given a consensus rating of “Buy” by the seven analysts that are covering the stock, Marketbeat.com reports. Canaccord Genuity ...
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoCytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript May 9, 2024 Cytokinetics,...
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...
GuruFocus.com via Yahoo Finance· 2 days agoPositive top-line results from the SEQUOIA-HCM Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy were highlighted ...